Compound hub
Retatrutide
Retatrutide (LY3437943) is an experimental Eli Lilly peptide described in the published literature as acting on three receptor systems at once. This hub collects the questions people ask about it and answers each one from the trial record.
Record card
| Common name | retatrutide |
|---|---|
| Research code | LY3437943 |
| Developer | Eli Lilly |
| CAS | 2381089-83-2 |
| Discovery year | 2022 |
| Trial phase as of 2026 | Phase 3 |
| Approval as of 2026 | Approved in no country |
Questions answered here
09- Retatrutide vs Mounjaro vs Ozempic: what's the difference?Retatrutide, Mounjaro, and Ozempic compared by molecule, receptor systems, and approval status. Research material is not a medicine.Updated 2026-08-18
- How long has retatrutide been studied?Retatrutide's research record from the first dated human enrollment in December 2019 to Phase 3 in 2026. Research material is not a medicine.Updated 2026-08-19
- Retatrutide pharmacokinetics: what is the half-life?Retatrutide's published human pharmacokinetics: a half-life of about six days, and what has not been measured. Research material is not a medicine.Updated 2026-08-20
- Retatrutide Phase 2 trial: what did the paper find?A guided read of the retatrutide Phase 2 obesity trial (NEJM 2023): 338 adults, 48 weeks, and what the primary end point actually measured.Updated 2026-08-21
- What is the molecular formula of retatrutide?Retatrutide molecular formula: C221H342N46O68, the registry record it comes from, and what a count of atoms cannot prove. Research use only.Updated 2026-10-01
- NCT05882045: what is the TRIUMPH-3 retatrutide trial?NCT05882045 is TRIUMPH-3, a Phase 3 retatrutide trial in obesity with cardiovascular disease. Registry status, enrolment, endpoint, and no posted results.Updated 2026-08-24
- NCT05929066: what is the TRIUMPH-1 retatrutide trial?NCT05929066 is TRIUMPH-1, a Phase 3 retatrutide trial in obesity without type 2 diabetes. Registry status, enrolment, nested sub-studies, no posted results.Updated 2026-08-28
- Where does tirzepatide come from? Lilly's LY3298176Tirzepatide began as Eli Lilly's LY3298176, a 39-amino-acid peptide engineered on a GIP backbone. What the published papers show, and what they do not.Updated 2026-08-28
- SURPASS and SURMOUNT: what the tirzepatide trials measuredSURPASS trials measured HbA1c in type 2 diabetes. SURMOUNT trials measured body weight. Two named tirzepatide programmes, two different questions.Updated 2026-10-01
Form Laboratories supplies research-use-only reference material. Everything in this hub is an educational summary of published third-party literature. It is not medical advice, not a use instruction, and research material is not for human or animal use.